Evidence of lifestyle modification in the management of hypercholesterolemia

Current Cardiology Reviews

Volumn 9, Issue 1, 2013, Pages 2-14

  Mannu, G S ^a   Zaman, M J S ^b,c   Gupta, A ^d   Rehman, H U ^e   Myint, P K ^a,f  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d WEST WALES GENERAL HOSPITAL   (United Kingdom)

^e REGINA QU APPELLE HEALTH REGION   (Canada)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Coronary heart disease (CHD); CVD risk; Hypercholesterolemia; Lifestyle modification

Indexed keywords

CHOLESTIN; FISH OIL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; SOYBEAN PROTEIN; STANOZOLOL; TRIACYLGLYCEROL; XUEZHIKANG;

ALCOHOL CONSUMPTION; ALMOND; BRAIN ISCHEMIA; CACAO; CHOLESTEROL BLOOD LEVEL; DIET; EVIDENCE BASED PRACTICE; FUNCTIONAL FOOD; GARLIC; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING; SMOKING CESSATION; SOYBEAN; TEA; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 84875868493     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403x11309010002     Document Type: Review

References (163)

1. Gibler Wb, Cannon Cp, Blomkalns Al, et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 2005; 111(20): 2699-2710.
2. Lloyd-Jones Dm, Larson Mg, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353(9147): 89-92.
3. Duvall Wl, Vorchheimer Da. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004; 17(1): 51-61.
4. Yusuf S, John Cairns J, Camm J, Fallen El, Gersh Bj. Evidence-Based Cardiology. John Wiley & Sons, Incorporated, 2003; 3-15.
5. Verschuren Wm, Jacobs Dr, Bloemberg Bp, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274(2): 131-136.
6. Larosa Jc, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990: 81(5): 1721-1733.
7. Law Mr, Wald Nj, Thompson Sg. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308(6925): 367-372.
8. Lipid_Research_Clinics_Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251(3): 351-364.
9. Ncep. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
10. Stamler J, Wentworth D, Neaton Jd. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256(20): 2823-2828.
11. Chen Z, Peto R, Collins R, Macmahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303(6797): 276-282.
12. Wilson Pw, Anderson Km, Castelli Wp. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med 1991; 90(1): 11-16.
13. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl A, A2-11.
14. Sever Ps, Dahlof B, Poulter Nr, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
15. Downs Jr, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-1622.
16. Manninen V, Elo Mo, Frick Mh, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260(5): 641-651.
17. Shepherd J, Cobbe Sm, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301-1307.
18. Colhoun Hm, Betteridge Dj, Durrington Pn, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
19. Scandinavian_Simvastatin_Survival_Study_Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
20. Lipid_Study_Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349-1357.
21. Heart_Protection_Study_Collaborative_Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
22. Larosa Jc, Grundy Sm, Waters Dd, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-1435.
23. Studer M, Briel M, Leimenstoll B, Glass Tr, Bucher Hc. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165(7): 725-730.
24. Ray Kk, Cannon Cp, Mccabe Ch, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46(8): 1405-1410.
25. O'keefe Jh, Jr., Cordain L, Harris Wh, Moe Rm, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43(11): 2142-2146.
26. Ncep. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-3421.
27. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a casecontrol study. Lancet 2005; 366(9497): 1640-1649.
28. Nordoy A, Goodnight Sh. Dietary lipids and thrombosis. Relationships to atherosclerosis. Arteriosclerosis 1990; 10(2): 149-163.
29. Ascherio A, Willett Wc. Health effects of trans fatty acids. Am J Clin Nutr 1997; 66(4 Suppl): 1006S-1010S.
30. Clifton Pm, Keogh Jb, Noakes M. Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr 2004; 134(4): 874-879.
31. Connor We, Defrancesco Ca, Connor Sl. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann N Y Acad Sci 1993; 683: 16-34.
32. Rudel Ll, Parks Js, Sawyer Jk. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15(12): 2101-2110.
33. Kris-Etherton P, Daniels Sr, Eckel Rh, et al. Summary of the scientific conference on dietary fatty acids and cardiovascular health: conference summary from the nutrition committee of the American Heart Association. Circulation 2001; 103(7): 1034-1039.
34. Nice. Identification and management of familial hypercholesterolaemia. National Institute for Health and Clinical Excellence 2008; CG71: 120.
35. Harris Ws. Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk? Curr Atheroscler Rep 2004; 6(6): 447-452.
36. Keys a Aj, Grande F. Serum cholesterol response to changes in diet, IV: particular saturated fatty acids in the diet. Metabolism 1965; 14: 776-787.
37. Km Km, Brand Miller J, Pollicino C, et al. Diets with a lower glycaemic load associated with higher HDL-cholesterol in secondary cardiovascular disease. Asia Pac J Clin Nutr 2003; 12(Suppl): S22.
38. Mccarron Da, Oparil S, Chait A, et al. Nutritional management of cardiovascular risk factors. A randomized clinical trial. Arch Intern Med 1997; 157(2): 169-177.
39. D W. International Task Force for prevention of coronary heart disease/International Atherosclerosis Society. Coronary Heart Disease. Reducing the risk. Nutr Metab Cardiovascular D 1998; 8: 205-271.
40. Schaefer Ej. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 2002; 75(2): 191-212.
41. Harris Ws, Connor We, Illingworth Dr, Rothrock Dw, Foster Dm. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 1990; 31(9): 1549-1558.
42. Sullivan Dr, Sanders Ta, Trayner Im, Thompson Gr. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis 1986; 61(2), 129-134.
43. Gunnarsdottir I, Tomasson H, Kiely M, et al. Inclusion of fish or fish oil in weight-loss diets for young adults: effects on blood lipids. Int J Obes (Lond) 2008; 32(7), 1105-1112.
44. Layne Ks, Goh Yk, Jumpsen Ja, Ryan Ea, Chow P, Clandinin Mt. Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels. J Nutr 1996; 126(9), 2130-2140.
45. Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol 2009; 64(3): 321-327.
46. Beil Fu, Terres W, Orgass M, Greten H. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. Atherosclerosis 1991; 90(1): 95-97.
47. Eslick Gd, Howe Pr, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009; 136(1): 4-16.
48. Robinson Jg, Stone Nj. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 2006; 98(4A): 39i-49i.
49. Mattar M, Obeid O. Fish oil and the management of hypertriglyceridemia. Nutr Health 2009; 20(1): 41-49.
50. Erkkila At, Schwab Us, De Mello Vd, et al. Effects of fatty and lean fish intake on blood pressure in subjects with coronary heart disease using multiple medications. Eur J Nutr 2008; 47(6): 319-328.
51. Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990; 227(5): 347-353.
52. Bairati I, Roy L, Meyer F. Effects of a fish oil supplement on blood pressure and serum lipids in patients treated for coronary artery disease. Can J Cardiol 1992; 8(1): 41-46.
53. Holub Dj, Holub Bj. Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem 2004; 263(1-2): 217-225.
54. Nice. Post Myocardial Infarction Secondary prevention in primary and secondary care for patients following a myocardial infarction Full guideline-Final Version NICE Guidelines 2007.
55. Kim Sh, Kim Mk, Lee Hy, Kang Hj, Kim Yj, Kim Hs. Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability. Eur J Clin Nutr 2011; 65(1): 110-116.
56. Brinson Be, Miller S. Fish oil: what is the role in cardiovascular health? J Pharm Pract 2012; 25(1): 69-74.
57. Bays He, Mckenney J, Maki Kc, Doyle Rt, Carter Rn, Stein E. Effects of prescription omega-3-acid ethyl esters on non-highdensity lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010; 85(2): 122-128.
58. Zhan S, Ho Sc. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005; 81(2): 397-408.
59. Anderson Jw, Bush Hm. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr 2011 30(2), 79-91.
60. Wong Jm, Kendall Cw, De Souza R, et al. The effect on the blood lipid profile of soy foods combined with a prebiotic: a randomized controlled trial. Metabolism 2010; 59(9): 1331-1340.
61. Chan Yh, Lau Kk, Yiu Kh, et al. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr 2007; 86(4): 938-945.
62. Khan Sa, Chatterton Rt, Michel N, et al. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 2012; 5(2): 309-319.
63. Sacks Fm, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113(7): 1034-1044.
64. Escurriol V, Cofan M, Serra M, et al. Serum sterol responses to increasing plant sterol intake from natural foods in the Mediterranean diet. Eur J Nutr 2009; 48(6), 373-382.
65. Acnfp. Cholesterol Lowering: Foods with added plant sterols. Cholesterol Lowering: Foods with added plant sterols 2005; 2012(24/07/2012).
66. Plat J, Mensink Rp. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol 2005; 96(1A), 15D-22D.
67. Mensink Rp, De Jong A, Lutjohann D, Haenen Gr, Plat J. Plant stanols dose-dependently decrease LDL-cholesterol concentrations, but not cholesterol-standardized fat-soluble antioxidant concentrations, at intakes up to 9 g/d. Am J Clin Nutr 2010; 92(1): 24-33.
68. Talati R, Sobieraj Dm, Makanji Ss, Phung Oj, Coleman Ci. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc 2010; 110(5): 719-726.
69. Doggrell Sa. Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011? Complement Ther Med 2011; 19(1): 37-46.
70. Grundy Sm. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol 2005; 96(1A): 47D-50D.
71. Nityanand S, Srivastava Js, Asthana Op. Clinical trials with gugulipid. A new hypolipidaemic agent. J Assoc Physicians India 1989; 37(5): 323-328.
72. Singh Rb, Niaz Ma, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994; 8(4): 659-664.
73. Urizar Nl, Moore Dd. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 2003; 23: 303-313.
74. Szapary Po, Wolfe Ml, Bloedon Lt, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003; 290(6): 765-772.
75. Ulbricht C, Basch E, Szapary P, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005; 13(4), 279-290.
76. Heber D, Yip I, Ashley Jm, Elashoff Da, Elashoff Rm, Go Vl. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69(2): 231-236.
77. Bogsrud Mp, Ose L, Langslet G, et al. HypoCol (red yeast rice) lowers plasma cholesterol-a randomized placebo controlled study. Scand Cardiovasc J 2012; 44(4): 197-200.
78. Klimek M, Wang S, Ogunkanmi A. Safety and Efficacy of Red Yeast Rice (Monascus purpureus) as an Alternative Therapy for Hyperlipidemia. P T 2009; 34(6): 313-327.
79. Gordon Ry, Becker Dj. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011; 13(1): 73-80.
80. Shang Q, Liu Z, Chen K, Xu H, Liu J. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart dis ease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012; 636547.
81. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101(12): 1689-1693.
82. Halbert Sc, French B, Gordon Ry, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105(2): 198-204.
83. Hooper L, Kay C, Abdelhamid A, et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr 2012; 95(3): 740-751.
84. Tokede Oa, Gaziano Jm, Djousse L. Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur J Clin Nutr 2011; 65(8): 879-886.
85. Jia L, Liu X, Bai Yy, et al. Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2010; 92(1): 218-225.
86. Shrime Mg, Bauer Sr, Mcdonald Ac, Chowdhury Nh, Coltart Ce, Ding El. Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. J Nutr 2011; 141(11): 1982-1988.
87. Hooper L, Kroon Pa, Rimm Eb, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88(1): 38-50.
88. Curtis Pj, Sampson M, Potter J, Dhatariya K, Kroon Pa, Cassidy A. Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2 diabetes: a 1-year, double-blind, randomized, controlled trial. Diabetes Care 35(2): 226-232
89. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296(10): 1255-1265.
90. Suzuki E, Yorifuji T, Takao S, et al. Green tea consumption and mortality among Japanese elderly people: the prospective Shizuoka elderly cohort. Ann Epidemiol 2009; 19(10): 732-739.
91. Reinhart Km, Talati R, White Cm, Coleman Ci. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 2009; 22(1): 39-48.
92. Khoo Ys, Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 2009; 34(2): 133-145.
93. Alder R, Lookinland S, Berry Ja, Williams M. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. J Am Acad Nurse Pract 2003; 15(3): 120-129.
94. Stevinson C, Pittler Mh, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 2000; 133(6): 420-429.
95. Phung Oj, Makanji Ss, White Cm, Coleman Ci. Almonds have a neutral effect on serum lipid profiles: a meta-analysis of randomized trials. J Am Diet Assoc 2009; 109(5): 865-873.
96. Covas Mi, Nyyssonen K, Poulsen He, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med 2006;145(5): 333-341.
97. Nordmann Aj, Suter-Zimmermann K, Bucher Hc, et al. Metaanalysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011; 124(9): 841-851 e842.
98. Kastorini Cm, Milionis Hj, Esposito K, Giugliano D, Goudevenos Ja, Panagiotakos Db. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011; 57(11): 1299-1313.
99. Eaton Cb. Relation of physical activity and cardiovascular fitness to coronary heart disease, Part I: A meta-analysis of the independent relation of physical activity and coronary heart disease. J Am Board Fam Pract 1992; 5(1): 31-42.
100. Nih. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 1996; 276(3): 241-246.
101. Durstine Jl, Grandjean Pw, Cox Ca, Thompson Pd. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 2002; 22(6): 385-398.
102. Whelton Sp, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136(7): 493-503.
103. Kelley Ga, Kelley Ks, Tran Zv. Walking and resting blood pressure in adults: a meta-analysis. Prev Med 2001; 33(2 Pt 1): 120-127.
104. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med 2004; 34(6): 371-418.
105. Thompson Pd, Buchner D, Pina Il, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107(24): 3109-3116.
106. Wood Pd, Haskell W, Klein H, Lewis S, Stern Mp, Farquhar Jw. The distribution of plasma lipoproteins in middle-aged male runners. Metabolism 1976; 25(11): 1249-1257.
107. Juonala M, Magnussen Cg, Berenson Gs, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365(20): 1876-1885.
108. King Ac, Haskell Wl, Young Dr, Oka Rk, Stefanick Ml. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995; 91(10): 2596-2604.
109. Duncan Ge, Anton Sd, Sydeman Sj, et al. Prescribing exercise at varied levels of intensity and frequency: a randomized trial. Arch Intern Med 2005; 165(20): 2362-2369.
110. Sunami Y, Motoyama M, Kinoshita F, et al. Effects of lowintensity aerobic training on the high-density lipoprotein cholesterol concentration in healthy elderly subjects. Metabolism 1999; 48(8): 984-988.
111. Kelley Ga, Kelley Ks. Aerobic exercise and HDL2-C: a metaanalysis of randomized controlled trials. Atherosclerosis 2006; 184(1): 207-215.
112. Kelley Ga, Kelley Ks, Roberts S, Haskell W. Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. BMC Med 2011; 9: 74.
113. Kelley Ga, Kelley Ks. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 2009; 48(1): 9-19.
114. Wood Pd, Stefanick Ml, Williams Pt, Haskell Wl. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991; 325(7): 461-466.
115. Roth Sm, Rankinen T, Hagberg Jm, et al. Advances in exercise, fitness, and performance genomics in 2011. Med Sci Sports Exerc 2012; 44(5): 809-817.
116. Williams Pt, Krauss Rm, Stefanick Ml, Vranizan Km, Wood Pd. Effects of low-fat diet, calorie restriction, and running on lipoprotein subfraction concentrations in moderately overweight men. Metabolism 1994; 43(5): 655-663.
117. Williams Pt, Krauss Rm, Vranizan Km, Wood Pd. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation 1990; 81(4): 1293-1304.
118. Kelley Ga, Kelley Ks, Tran Zv. Exercise, lipids, and lipoproteins in older adults: a meta-analysis. Prev Cardiol 2005; 8(4): 206-214.
119. Kelley Ga, Kelley Ks. Aerobic exercise and lipids and lipoproteins in children and adolescents: a meta-analysis of randomized controlled trials. Atherosclerosis 2007; 191(2): 447-453.
120. Mora S, Yanek Lr, Moy Tf, Fallin Md, Becker Lc, Becker Dm. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation 2005; 111(15), 1871-1876.
121. Halle M, Berg A, Garwers U, Grathwohl D, Knisel W, Keul J. Concurrent reductions of serum leptin and lipids during weight loss in obese men with type II diabetes. Am J Physiol 1999; 277(2 Pt 1); E277-282.
122. Hawkins Ri. Smoking, platelets and thrombosis. Nature 1972; 236(5348): 450-452.
123. Meade Tw, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2(8566): 986-988.
124. Lakier Jb. Smoking and cardiovascular disease. Am J Med 1992; 93(1A): 8S-12S.
125. Kottke Te, Battista Rn, Defriese Gh, Brekke Ml. Attributes of successful smoking cessation interventions in medical practice. A meta-analysis of 39 controlled trials. JAMA 1988; 259(19): 2883-2889.
126. Ford Cl, Zlabek Ja. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005; 80(5): 652-656.
127. Richmond R, Zwar N. Review of bupropion for smoking cessation. Drug Alcohol Rev 2003; 22(2): 203-220.
128. Lancaster T, Stead Lf. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD001292.
129. Stead Lf, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD001007.
130. Nakamura K, Barzi F, Huxley R, et al. Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? Heart 2009; 95(11): 909-916.
131. Craig Wy, Palomaki Ge, Johnson Am, Haddow Je. Cigarette smoking-associated changes in blood lipid and lipoprotein levels in the 8-to 19-year-old age group: a meta-analysis. Pediatrics 1990; 85(2): 155-158.
132. Jee Sh, Park J, Jo I, et al. Smoking and atherosclerotic cardiovascular disease in women with lower levels of serum cholesterol. Atherosclerosis 2007; 190(2): 306-312.
133. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003; 37(4), 283-290.
134. Baraona E, Lieber Cs. Fatty liver, hyperlipemia, and erythrocyte alterations produced by ethanol feeding in the rat. Am J Clin Nutr 1969; 22(3), 356-357.
135. Baraona E, Lieber Cs. Efcts of chronic ethanol feeding on serum lipoprotein metabolism in the rat. J Clin Invest 1970; 49(4): 769-778.
136. Baraona E, Pirola Rc, Lieber Cs. Pathogenesis of postprandial hyperlipemia in rats fed ethanol-containing diets. J Clin Invest 1973; 52(2): 296-303.
137. Brien Se, Ronksley Pe, Turner Bj, Mukamal Kj, Ghali Wa. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011; 342: d636.
138. Ronksley Pe, Brien Se, Turner Bj, Mukamal Kj, Ghali Wa. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: d671.
139. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004; 38(5): 613-619.
140. Pedersen Jo, Heitmann Bl, Schnohr P, Gronbaek M. The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality. Eur Heart J 2008; 29(2): 204-212.
141. Prochaska Jo, Velicer Wf. The transtheoretical model of health behavior change. Am J Health Promot 1997; 12(1): 38-48.
142. Glanz K, Rimer Bk, Viswanath K. Health Behavior and Health Education: Theory, Research, and Practice. John Wiley & Sons, 2008.
143. Somerset Sm, Graham L, Markwell K. Depression scores predict adherence in a dietary weight loss intervention trial. Clin Nutr 2011; 30(5): 593-598.
144. Pollak Ki, Alexander Sc, Coffman Cj, et al. Physician communication techniques and weight loss in adults: Project CHAT. Am J Prev Med 2010; 39(4): 321-328.
145. Armstrong Mj, Mottershead Ta, Ronksley Pe, Sigal Rj, Campbell Ts, Hemmelgarn Br. Motivational interviewing to improve weight loss in overweight and/or obese patients: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2011; 12(9): 709-723.
146. Pollak Ki, Coffman Cj, Alexander Sc, et al. Predictors of weight loss communication in primary care encounters. Patient Educ Couns 2011; 85(3), e175-182.
147. Cox Me, Yancy Ws, Jr., Coffman Cj, et al. Effects of counseling techniques on patients' weight-related attitudes and behaviors in a primary care clinic. Patient Educ Couns 2011; 85(3): 363-368.
148. Bihan H, Takbou K, Cohen R, et al. Impact of short-duration lifestyle intervention in collaboration with general practitioners in patients with the metabolic syndrome. Diabetes Metab 2009; 35(3): 185-191.
149. Digenio Ag, Mancuso Jp, Gerber Ra, Dvorak Rv. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med 2009; 150(4): 255-262.
150. Resnick He, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 2003; 26(3): 861-867.
151. Allhat. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23): 2998-3007.
152. Sacks Fm, Pfeffer Ma, Moye La, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001-1009.
153. Shepherd J, Blauw Gj, Murphy Mb, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623-1630.
154. Rose G. Sick individuals and sick populations, 1985. Bull World Health Organ 2001; 79(10): 990-996.
155. Zaman Mj, Sanders J, Crook Am, et al. Cardiothoracic ratio within the "normal" range independently predicts mortality in patients undergoing coronary angiography. Heart 2007; 93(4): 491-494.
156. Van Duijn Hj, Belo Jn, Blom Jw, Velberg Id, Assendelft Wj. Revised guidelines for cardiovascular risk management-time to stop medication? A practice-based intervention study. Br J Gen Pract 2011; 61(587): e347-352.
157. Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland. Circulation 1998; 97(11): 1087-1094.
158. Puska P. Nutrition and mortality: the Finnish experience. Acta Cardiol 2000; 55(4): 213-220.
159. Mckeigue Pm, Miller Gj, Marmot Mg. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol 1989; 42(7): 597-609.
160. Gupta A, Guyomard V, Zaman Mj, Rehman Hu, Myint Pk. Systematic review on evidence of the effectiveness of cholesterollowering drugs. Adv Ther 2010; 27(6): 348-364.
161. Spriston K Pp. Risk factors for cardiovascular disease. Health Survey for England 2003. London: The Stationery Office, vol 2.
162. Williams B, Poulter Nr, Brown Mj et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328(7440): 634-640.
163. Nice. Lipid modification (CG67). Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008.